<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01054443</url>
  </required_header>
  <id_info>
    <org_study_id>0913M0621</org_study_id>
    <nct_id>NCT01054443</nct_id>
  </id_info>
  <brief_title>A Study to Investigate the Efficacy and Safety of S-888711 Tablets Administered to Adult Subjects With Immune Thrombocytopenia (ITP)</brief_title>
  <official_title>A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of S-888711 Tablets Administered Once-daily for 42 Days to Adult Subjects With Relapsed Persistent or Chronic Immune Thrombocytopenia With or Without Prior Splenectomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shionogi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shionogi Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 2, multicenter, randomized, double-blind, placebo-controlled, dose-ranging,
      parallel-group study to evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics
      of S-888711 in the treatment of subjects with immune thrombocytopenia. Eligible subjects will
      be randomized into one of four treatment groups to receive S-888711 0.5 mg, 0.75 mg, or 1.0
      mg or placebo.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    The study objectives became unachievable as a result of the termination of 0913M0621
  </why_stopped>
  <start_date>January 2010</start_date>
  <completion_date type="Actual">December 2010</completion_date>
  <primary_completion_date type="Actual">November 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary efficacy endpoint is the proportion of responder subjects in each treatment group</measure>
    <time_frame>6-weeks</time_frame>
    <description>The responders were subjects with 1) achieved a platelet count of ≥ 50, 000/µL after 6 weeks of dosing 2) prematurely withdrawn due to a platelet count &gt; 400,000/ µL prior to Day 42</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety of S-888711</measure>
    <time_frame>6-weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK) profile of S-888711 using sparse PK sampling</measure>
    <time_frame>6-weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK profile of S-888711 using serial PK sampling in a selected subset of subjects</measure>
    <time_frame>6-weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK/PD relationship of S-888711 with respect to platelet count</measure>
    <time_frame>6-weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impact of S-888711 on the incidence and severity of bleeding</measure>
    <time_frame>6-weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic (PD) effect of S-888711 on platelet count and markers of platelet function, such as endogeneous thrombopoietin (TPO)</measure>
    <time_frame>6-weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">19</enrollment>
  <condition>Immune Thrombocytopenia (ITP)</condition>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>0.5 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>0.75 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>1.0 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo to S-888711</intervention_name>
    <description>Tablet</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>S-888711</intervention_name>
    <description>Tablet</description>
    <arm_group_label>0.5 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>S-888711</intervention_name>
    <description>Tablet</description>
    <arm_group_label>0.75 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>S-888711</intervention_name>
    <description>Tablet</description>
    <arm_group_label>1.0 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  A signed and dated written informed consent

          -  Males and females ≥ 18 years of age

          -  All subjects must agree to use barrier contraception

          -  Diagnosis of ITP

          -  Subjects &gt; 60 years must have had a diagnostic bone marrow aspiration

          -  Relapsed persistent or chronic ITP status, with or without prior splenectomy
             (exception: in Hungary only splenectomized subjects will be enrolled), after having
             failed at least 1 prior ITP therapy (excluding TPO agonists) and have a platelet count
             &lt; 30,000/μL if not taking medications or &lt; 50,000/μL despite concomitant steroids or
             other ITP therapies, such as danazol or immunosuppressive drugs

          -  Subjects receiving steroid therapy must be on a stable dose

          -  PT and APTT within 20% of the upper limit of normal

          -  Subjects receiving stable dosages of cyclosporine A, mycophenolate mofetil,
             azathioprine, or danazol are allowed. The dosages of all these medications must be
             stable for at least 4 weeks prior to Visit 1 (Day 1)

        Exclusion Criteria:

          -  History of clinically important hemorrhagic clotting disorder

          -  Females who are pregnant, lactating, or taking oral contraceptives

          -  History of alcohol/drug abuse or dependence within 1 year

          -  Use of the following drugs or treatment prior to Visit 1 (Day 1):

               -  Within 12 weeks - alemtuzumab, multi-drug systemic chemotherapy, stem cell
                  therapy;

               -  Within 8 weeks - rituximab

               -  Within 2 weeks - platelet transfusions or plasmapheresis treatment

               -  Within 4 weeks - use of anti-platelet or anti-coagulant drugs

               -  Within 1 week - Rho(D) immune globulin or intravenous immunoglobulin

          -  History of clinically significant cardiovascular or thromboembolic disease within 26
             weeks prior to Screening

          -  Splenectomy within 4 weeks prior to Screening

          -  Clinically significant laboratory abnormalities

               -  Hemoglobin &lt; 10.0 g/dL for men or women, not clearly related to ITP

               -  Absolute neutrophil count &lt; 1000/mm3

               -  Abnormal peripheral blood smear

               -  Total bilirubin &gt; 1.5 x upper limit of normal

               -  Alanine aminotransferase (ALT) &gt; 1.5 x upper limit of normal

               -  Aspartate aminotransferase (AST) &gt; 1.5 x upper limit of normal

               -  Creatinine &gt; 1.5 x upper limit of normal

               -  Human immunodeficiency virus (HIV) positive

               -  Hepatitis A IgM antibody (IgM HAV) positive, hepatitis B surface antigen (HbsAg)
                  or hepatitis C antibody (HCV) positive

               -  Thyroid stimulating hormone (TSH) &gt; 1.5 x upper limit of normal

               -  Free thyroxine (T4) &gt; 1.5 x upper limit of normal

          -  Exposure to previous TPO mimetics/agonists (e.g., eltrombopag,romiplostim, E5501
             [AKR-501] or LGD-4665) within 4 weeks prior to Screening

          -  Subjects unresponsive to previous TPO mimetics/agonists (e.g., eltrombopag,
             romiplostim, E5501 [AKR-501] or LGD-4665)

          -  Exposure to an investigative medication within the past 30 days
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shionogi Clinical Trials Administrator Clinical Support Help Line</last_name>
    <role>Study Director</role>
    <affiliation>Shionogi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Investigator</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90272</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator</name>
      <address>
        <city>Boynton Beach</city>
        <state>Florida</state>
        <zip>33426</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30341</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator</name>
      <address>
        <city>Riverdale</city>
        <state>Georgia</state>
        <zip>30274</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator</name>
      <address>
        <city>Metairie</city>
        <state>Louisiana</state>
        <zip>70006</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator</name>
      <address>
        <city>Jefferson City</city>
        <state>Missouri</state>
        <zip>65109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator</name>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <zip>08903</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 20, 2010</study_first_submitted>
  <study_first_submitted_qc>January 20, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 22, 2010</study_first_posted>
  <disposition_first_submitted>May 18, 2018</disposition_first_submitted>
  <disposition_first_submitted_qc>May 18, 2018</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">May 22, 2018</disposition_first_posted>
  <last_update_submitted>May 18, 2018</last_update_submitted>
  <last_update_submitted_qc>May 18, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 22, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Blood Platelet Disorders</keyword>
  <keyword>Immune Thrombocytopenia (ITP)</keyword>
  <keyword>Low Platelet Count</keyword>
  <keyword>Thrombocytopaenia</keyword>
  <keyword>S-888711</keyword>
  <keyword>Splenectomy</keyword>
  <keyword>Thrombopoiesis</keyword>
  <keyword>Hematologic Disease</keyword>
  <keyword>Auto-immune thrombocytopenic Purpura</keyword>
  <keyword>Relapsed Persistent or Chronic ITP</keyword>
  <keyword>Idiopathic Thrombocytopenic Purpura</keyword>
  <keyword>Thrombotic Thrombocytopenic Purpura (TTP)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thrombocytopenia</mesh_term>
    <mesh_term>Purpura, Thrombocytopenic, Idiopathic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

